These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31960136)

  • 1. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study.
    Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P
    J Neurol; 2020 May; 267(5):1340-1347. PubMed ID: 31960136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.
    Samadzadeh S; Ürer B; Brauns R; Rosenthal D; Lee JI; Albrecht P; Hefter H
    Toxins (Basel); 2020 Aug; 12(8):. PubMed ID: 32759685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Secondary Treatment Failure during Incobotulinumtoxin-A Long-Term Treatment Demonstrated by the Drawing of Disease Severity.
    Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P; Samadzadeh S
    Toxins (Basel); 2023 Jul; 15(7):. PubMed ID: 37505723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    J Neurol; 2022 Nov; 269(11):5991-6002. PubMed ID: 35842881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin.
    Hefter H; Rosenthal D; Jansen A; Brauns R; Ürer B; Bigalke H; Hartung HP; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    J Neurol; 2023 Feb; 270(2):788-796. PubMed ID: 36195775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity.
    Bakheit AM; Liptrot A; Newton R; Pickett AM
    Int J Rehabil Res; 2012 Mar; 35(1):36-9. PubMed ID: 22108625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term adherence and response to botulinum toxin in different indications.
    Lee JI; Jansen A; Samadzadeh S; Kahlen U; Moll M; Ringelstein M; Soncin G; Bigalke H; Aktas O; Moldovan AS; Waskoenig J; Jander S; Gliem M; Schnitzler A; Hartung HP; Hefter H; Albrecht P
    Ann Clin Transl Neurol; 2021 Jan; 8(1):15-28. PubMed ID: 33259153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review.
    Mathevon L; Declemy A; Laffont I; Perennou D
    Ann Phys Rehabil Med; 2019 Jul; 62(4):241-251. PubMed ID: 30980953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin A: dose and immune response.
    Bigalke H; Frevert J
    Int J Rehabil Res; 2012 Jun; 35(2):93. PubMed ID: 22561214
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.
    Müller K; Mix E; Adib Saberi F; Dressler D; Benecke R
    J Neural Transm (Vienna); 2009 May; 116(5):579-85. PubMed ID: 19352590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia.
    Tilden D; Guarnieri C
    Value Health; 2016; 19(2):145-52. PubMed ID: 27021747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
    Walter U; Mühlenhoff C; Benecke R; Dressler D; Mix E; Alt J; Wittstock M; Dudesek A; Storch A; Kamm C
    Neurology; 2020 May; 94(20):e2109-e2120. PubMed ID: 32332130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
    Dressler D
    Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.